Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

FDA  Grants $4. 3 Million Small Business Waiver, Enabling Focus on Commercialization Preparations

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

The Company is in Advanced Stage s of Commercial U.S. Partner ship Discussions for D-PLEX₁₀₀

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

Appointment Enhances PolyPid's Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application Submission Appointment Enhances PolyPid's Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application Submission

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

PETACH TIKVA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a formal pre-New Drug Application (“NDA”) meeting minutes from the U.S. Food and Drug Administration (“FDA”) supporting the NDA submission of D-PLEX100, the Company's lead product candidate for the prevention of surgical site infections in abdominal colorectal surgeries.